Galderma Pharmaceutical Expands in Quebec
Location Canada 2010
Galderma, which produces the skin care line Cetaphil, received more than $38 million from Investissement Quebec, the province's investment program, which targets product development projects by Quebec companies. The sum includes a non-refundable $3.8 million financial contribution that will help Galderma modernize and expand its drug manufacturing plant in Bai-d'Urfe.
"The government's support was a decisive factor in Galderma's decision to locate its center of excellence in Quebec," says Michel Sauvageau, manager of the Bai-d'Urfe plant. "In response to the progress of emerging countries in biopharmaceuticals, this investment in our manufacturing facility will increase its capacity and make it truly state-of-the-art."
The funds will also allow Galderma to consolidate 240 positions and create 30 new, specialized jobs.
Project Announcements
Greece-Based METLEN Establishes Calgary, Alberta, Canada, Operations
11/29/2024
South Korea-Based Hanon Systems Plans Woodbridge, Ontario, Manufacturing Operations
11/09/2024
OmniaBio Plans Hamilton, Ontario, Manufacturing Operations
10/30/2024
Jungbunzlauer Expands Port Colborne, Ontario, Production Operations
10/14/2024
Bartlett Group Plans Strathcona County, Alberta, Headquarters-Manufacturing Operations
10/11/2024
Golden Windows Expands Kitchener, Ontario, Operations
09/06/2024
Most Read
-
2024's Leading Metro Locations: U.S. Cities on the Rise Amid an Economic Reshuffling
Q4 2024
-
Best Practices in Incentives Procurement
Q4 2024
-
How Automation Is Actually Closing the Labor Gap
Q4 2024
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Why Decarbonization Goals Start with Site Selection
Q4 2024
-
The Workforce Factor: How States Are Competing to Build Tomorrow's Talent
Q4 2024
-
Around the Horn with Amy Gerber and Kathy Mussio: Incentives and Workforce Development
Q4 2024